REG - Genedrive PLC - Notice of Results

GenedriveAnnouncement

14/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221114:nRSN1967Ga&default-theme=true

RNS Number : 1967G  Genedrive PLC  14 November 2022

 

genedrive plc

("genedrive" or the "Company")

 

Notice of Results

Investor Presentation

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics
company, announces it will release its preliminary results for the year
ended 30 June 2022 on Monday, 21 November 2022.

 

The Company will provide a live presentation to accompany the results,
presented by CEO, David Budd and CFO, Russ Shaw on Monday, 21 November 2022
at 12.00pm.

 

The presentation will be hosted through the digital platform Investor Meet
Company. Investors can sign up to Investor Meet Company for free and add
genedrive plc to meet the Company via the following
link: https://www.investormeetcompany.com/genedrive-plc/register-investor
(https://www.investormeetcompany.com/genedrive-plc/register-investor)

 

 

For further details please contact:

 

 genedrive plc                                              +44 (0)161 989 0245
 David Budd: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)         +44 (0)20 7418 8900
 James Steel
 Oliver Duckworth

 finnCap (Joint Broker)                                     +44 (0)20 7220 0500
 Geoff Nash / George Dollemore / Nigel Birks / Alice Lane

 Walbrook PR Ltd (Media & Investor Relations)              +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                           (mailto:genedrive@walbrookpr.com)
 Paul McManus / Anna Dunphy                                 +44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )  genedrive plc is a molecular diagnostics
company developing and commercialising a low cost, rapid, versatile, simple to
use and robust point of need molecular diagnostics platform for the diagnosis
of infectious diseases and for use in patient stratification (genotyping),
pathogen detection and other indications. The Company has assays on market for
the detection of HCV, certain military biological targets, and a  test to
help in the prevention of hearing loss caused by certain antibiotics in
neonates. The Company recently released point of care test for Covid-19.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBBBITMTIBBPT